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ABSTRACT 
Background and Purpose: Brain-derived neurotrophic factor (BDNF) levels have been reported to play 
an important role in driving neuroprotection in people with neurologic disorders, and levels of BDNF are 
known to increase in response to physical activity. Moreover, the level of BDNF produced is also 
affected by BDNF genotype. It is not known, however, whether one’s BDNF genotype interacts with 
physical activity throughout life to affect a neuroprotective response in people with Parkinson’s disease 
(PD). Therefore, the purpose of this study was to determine if BDNF genotype interacts with lifetime 
self-reported physical activity levels to affect disease severity and progression as determined by 
measures of gait, balance, and PD motor function. 
Methods: Included in the study were 28 individuals with idiopathic PD. DNA collected from buccal cells 
was used to determine BDNF genotype. Self-report measures included a modified version of the Lifetime 
Physical Activity Questionnaire (LPAQ), the Fear of Falling Avoidance Behavior Questionnaire (FFABQ), 
and the Activities-Specific Balance Confidence scale (ABC), as well as demographic information. Tester- 
administered measures included the Mini-Balance Evaluations Test (MiniBESTest), a gait and balance 
performance battery, and the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale III 
(MDS-UPDRS-III), an observational assessment of motor function. 
Results: There was not a significant interaction between BDNF genotype and self-reported history of 
physical activity on measures of gait and balance in individuals with PD. There was also no interaction 
between BDNF genotype and history of physical activity on age of PD onset or severity of disease. 
Discussion: Preliminary results did not reveal any differential effects of BDNF genotype and history of 
physical activity effecting gait and balance, age of disease onset, or disease severity in individuals with 
PD. While all of the analyses are currently underpowered due to sample size, there were trends to 
indicate that there may be some validity to the original hypotheses. Data collection for this study is 
ongoing. 
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INTRODUCTION 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that results in motor deficits 
including the cardinal signs of bradykinesia, rigidity, resting tremors, and postural instability.1 The death 
of neurons within the substantia nigra pars compacta (SNpc) is a notable feature of the pathology of 
PD.2 Normally, the SNpc releases dopamine that is utilized by the basal ganglia to up-regulate motor 
patterns within the cortex.3 Progressive attrition of these dopaminergic neurons appears to be the 
predominant cause for many of the motor signs associated with the disease, although a majority of the 
brain is eventually affected.4 
Physical activity is crucial in the treatment and prevention of PD. Regular moderate to vigorous aerobic 
exercise throughout life has been repeatedly shown in epidemiologic research to decrease the risk of 
developing PD,5–9 but the mechanism for this protection is not fully understood. One hypothesis is that 
these effects are mediated in part by physical activity-related increases in the production of brain- 
derived neurotrophic factor (BDNF).10,11 BDNF contributes to motor learning and sustained motor 
function possibly by promoting cell division or neuronal trafficking, regulating neuronal plasticity, and 
preventing premature neuronal cell death,11,12 including protection of dopaminergic neurons.13,14 High- 
intensity aerobic exercise increases BDNF immediately after just one bout15–18 and is associated with 
increased motor learning and declarative memory in healthy subjects,19 those with a history of stroke 
(CVA),20–23 those with Alzheimer’s disease (AD),10,11,19,24 and those with PD.14,25,26 
An individual’s specific BDNF genotype, however, mediates the amount of BDNF ultimately produced. A 
functional single nucleotide polymorphism (SNP) of this gene commonly exists in which the valine at 
position 66 of the BDNF precursor polypeptide is substituted for methionine, commonly known as the 
Val66Met polymorphism. The presence of this amino acid substitution ultimately decreases the amount 
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of BDNF that is produced.25 In mice, the homozygous Val/Val genotype results in the greatest production 
of BDNF after cerebral ischemic infarct.22 In individuals with Alzheimer’s disease, heterozygous Met 
carriers have higher rates of atrophy in the hippocampus over time, which is an AD-related marker of 
neurodegeneration.27 In mice post-cerebral infarct, the homozygous Met/Met genotype results in the 
lowest average production of BDNF, shown to be less than half of their Val/Val counterparts at certain 
stages of recovery following cerebral ischemic infarct.22 
 
 
Initial studies suggest that this genetic polymorphism and aerobic activity levels may influence BDNF 
production simultaneously.12,21 For instance, subjects post-CVA with a Val/Val genotype had a better 
response to aerobic exercise and activities to promote motor learning than participants with the Met 
allele.21 While it appears unlikely that the Val66Met polymorphism alone affects the age of onset of 
PD,12 it is possible that an interaction between BDNF genotype and history of physical activity may 
confer benefits for this population. However, no studies have investigated the effect of this interaction 
on PD onset and severity or on the level of function of individuals with PD. Therefore, the purpose of 
this study was to determine if BDNF genotype interacts with lifetime self-reported physical activity levels 
to affect the degree of disease severity as determined by measures of gait and postural stability, as well 
as age of onset in individuals with PD. 
 
 
This study was shaped by two aims. Primary Aim 1 was to determine if there was an interaction between 
BDNF genotype and history of physical activity on measures of gait and postural stability in individuals 
with PD. We hypothesized that individuals with a homozygous Val/Val genotype and high levels of 
aerobic activity throughout the lifespan would have reduced disease severity as indicated by better gait 
and postural stability measures than other genotypes with similar or lower activity levels. Primary Aim 2 
was to determine if there was an interaction between BDNF genotype and history of physical activity on 
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year of PD onset. We hypothesized that individuals with a homozygous Val/Val genotype and high levels 
of aerobic activity throughout the lifespan would be diagnosed later in life compared to the other BDNF 
genotypes with similar activity levels. 
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METHODS 
 
Study Design 
 
A cross-sectional design was used for the study. BDNF genotype was determined using buccal cells and 
polymerase chain reaction (PCR). This method was preferred as it is quick, safe, non-invasive, and 
relatively inexpensive. Physical activity throughout the lifespan was measured using a modified version 
of the Lifetime Physical Activity Questionnaire (LPAQ) initially developed and validated by Chasan-Taber 
et al.28 The questionnaire inquired about time spent sitting, walking, performing moderate activity, and 
performing vigorous activity during a total of seven life stages (teens, twenties, thirties, forties, fifties, 
during the five years before diagnosis with PD, and during the time since diagnosis with PD). Self- 
reporting of habitual physical activity of various intensities across different stages of the lifespan has 
been shown to have reliability, validity and reproducibility in the LPAQ as well as by other developers of 
similar questionnaires.29,30 Additionally, we tested for reliability of our survey in people with PD by 
recruiting 15 (age= 64.3 years, SD= 4.9; males= 10, females= 5; Montreal Cognitive Assessment=27.2, 
SD=2.0; years since diagnosis=8.1, SD=5.5) of our participants to receive a second copy of the survey one 
week after initial testing either by e-mail or postal mail returned via a postage-paid envelope. An 
Intraclass Correlation Coefficient (ICC) model 3 showed moderate and vigorous physical activity 
recollection ranged from .77 to .91 for all of the time points between 20-29 years to 5 years before 
diagnosis. ICCs for walking and sitting were much more variable for the same time periods and ranged 
from .29 to .82. ICCs for the teen years were low: <.001 for moderate activity, .55 for vigorous, .07 for 
walking, and .49 for sitting. Likewise, ICCs were generally low for the time since diagnosis (all below .25) 
except for vigorous activity which was .91, suggesting that the reliability of the LPAQ was best for 
recollection of vigorous activity for every time point. Despite the small sample size, the reliability of the 
self-report questionnaire about lifetime physical activity levels in people with Parkinson’s disease was 
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good for recollection of moderate and vigorous physical activity at almost all time points with vigorous 
activity having the most consistent test-retest reliability. 
 
 
Gait and balance function was quantified using subject-reported measures, including the Fear of Falling 
Avoidance-Behavior Questionnaire (FFABQ)31 and the Activities-Specific Balance Confidence Scale 
(ABC),32 as well as a clinician-administered measure, the Mini-BESTest33, all of which have been shown to 
have excellent inter-rater and intra-rater reliability and construct validity in the PD population. The ABC 
has excellent test-retest reliability (ICC=0.94)34 and excellent internal consistency (Cronbach’s alpha = 
0.92-0.96)34,35 in individuals with PD. The ABC correlated with the FFABQ (r = -0.68, p < 0.01).31 The 
FFABQ has good test-retest reliability (ICC =0.81) and is valid in differentiating between elderly adults 
who fall and those who do not.31 The Mini-BESTest has excellent test-retest reliability (ICC = 0.92),36 
excellent concurrent validity with the Berg Balance Test,37–39 and excellent ability to detect balance 
deficits in Hoehn and Yahr stages 1-2 with superior disease severity detection to the Berg Balance 
Scale.38 Disease severity was measured using the motor subscale (section 3) of the Movement Disorder 
Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)40 and the Hoehn & Yahr Scale. The 
Hoehn & Yahr Scale was selected since it shows stronger reliability and validity in categorizing the 
progression of PD than the Modified Hoehn & Yahr.41 The MDS-UPDRS is the most widely used scale for 
rating the severity of PD and the validity, inter-rater and intra-rater reliability of this instrument are well 
documented.42–44 Figure 1 below summarizes the data collection protocol followed for all participants in 
the study. 
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Figure 1. Data collection protocol 
 
 
 
 
Sample Size Calculation 
 
Sample size was estimated using PASS 14.0 (NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass) 
for Aim 1. The sample size estimation was based on three factors at 3 (Val/Val, Val/Met, and Met/Met), 
2 (Met CDC levels (CDC+) and did not meet CDC levels (CDC-)), and 4 levels (20s, 30s, 40s, and 50s) using 
a 3 X 3 X 4 factorial ANOVA with an alpha of .05 and power at 70%. This factorial design has 36 cells 
(treatment combinations). A total of 288 participants are required to provide 8 participants per cell with 
a within-cell standard deviation of 0.5 for a three-way interaction with an effect size of 0.4. 
 
 
Participants 
 
To be included, participants must have had neurologist-diagnosed idiopathic PD. Since there were 
several outcome measures that were self-report and required accurate recall, participants were 
excluded if they had cognitive impairment (scores <21) using the Montreal Cognitive Assessment 
(MoCA).45 The MoCA has been shown to have excellent test-retest reliability with an ICC = 0.97 and good 
validity for the detection of mild cognitive impairment in people with PD.46,47 Demographic data 
collected from each participant included age, gender, years since diagnosis, fall history, Hoehn and Yahr 
stage, LEDD (levodopa equivalent daily dose), and time since last medication dosage. Recruitment 
included snowball strategies with participants and recruiting visits to a movement disorders 
neurologist’s office, PD support groups, physical therapy clinics, and senior centers. Thirty individuals 
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with PD were enrolled in the study; however, two participants had MoCA scores lower than 21 and were 
excluded from the analysis. Thus, 28 participants met all of the inclusion/exclusion criteria (mean age = 
66.4±2.3; 21 males, 7 females; mean years since diagnosis = 8.9±5.5; fallers = 14, non-fallers = 14; Hoehn 
and Yahr stage I = 4, II = 15, III = 7, IV = 2; LEDD = 670.4±455.5; time since last medication = 3.3±4.1; 
Val/Val = 16, Val/Met = 12, Met/Met = 0) (Figure 2). 
 
 
Figure 2. CONSORT flow diagram of participants’ progress through study. 
 
 
• Excluded (n=6) 
• Transportation issues (n=2) 
• Unable to schedule time (n=1) 
• Lack of interest (n=3) 
 
 
 
• Excluded (n=2) 
• MoCA score <21 (n=2) 
 
 
 
 
 
Data Analysis 
 
Because the proposed sample size was not achieved during the data collection period, the proposed 
analyses were amended accordingly. To test Primary Aim 1, we segregated the data based on genotype 
(Val/Val and Val/Met or Met/Met) and, using chi square analyses (Yates’ continuity correction), we 
determined if there were differences in the proportions of self-report achievement of CDC levels of 
moderate to vigorous activity levels (CDC+ and CDC-) across each of the following life phases: 20s, 30s, 
40s, 50s, 5 years preceding diagnosis, and since diagnosis. We also compared the levels of activity for 
Data 
Collected 
(28) 
 
Contacted 
(36) 
Assessed for 
Eligibility 
(30) 
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each life phase using an ANCOVA for the following gait and balance outcomes: ABC, mFFABQ, and 
miniBESTest. BDNF genotype was also compared using non-parametric Kruskal-Wallis test on the same 
three gait and balance outcomes. This was also conducted for BDNF genotype. Covariates entered into 
the analyses were age, years since diagnosis, and whether or not one had a Deep Brain Stimulator (DBS). 
LEDD and time since last medication dose were not included as the correlations were not sufficiently 
strong (rs<.400). Chi square analyses were used to determine if there were proportional differences for 
fall history and Hoehn and Yahr stage based on achievement of CDC activity levels. Even though we were 
underpowered for the analyses, we conducted a factorial ANOVA to determine the effect size of the 
interaction to adjust the sample size as this is an ongoing trial. We conducted 2 (Val/Val and Val/Met or 
Met/Met) X 2 (CDC+ and CDC- for each of the aforementioned life phases) ANCOVAs on measures of gait 
and balance. For disease onset on Primary Aim 2, we compared the age of PD onset by BDNF genotype 
using non-parametric Mann-Whitney tests. We did the same for CDC activity levels at each life phase. 
For disease severity, we used the same factorial ANCOVA (2 (Val/Val and Val/Met or Met/Met) X 2 
(CDC+ and CDC-)) on MDS-UPDRS III using the same covariates. 
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RESULTS 
 
There were no statistically significant differences in the proportions meeting CDC activity criteria (CDC+ 
and CDC-) by BDNF genotype across each of the following life phases (20s, 30s, 40s, 50s, 5 years 
preceding diagnosis, since diagnosis) (Table 1). 
 
Table 1. Number of participants meeting CDC activity levels by BDNF genotype and life phase. 
 
 
Val/Val Val/Met or Met/Met 
P value 
20s CDC+
1 = 15 
CDC-2 = 1 
CDC+ = 10 
CDC- = 2 0.8 
30s CDC+ = 15 CDC- = 1 
CDC+ = 11 
CDC- = 1 1.0 
40s CDC+ = 13   CDC- = 3  
CDC+ = 9 
CDC- = 3  1.0 
50s CDC+ = 13   CDC- = 3  
CDC+ = 9 
CDC- = 3  1.0 
5 years preceding CDC+ = 13 CDC- = 3 
CDC+ = 11 
CDC- = 1 0.8 
Since diagnosis CDC+ = 13 CDC- = 3 
CDC+ = 10 
CDC- = 2 1.0 
1 CDC+ value represents individuals meeting CDC activity levels. 
2 CDC- value represents individuals not meeting CDC activity levels. 
 
 
There were no statistically significant differences in ABC scores across each of the life phases based on 
meeting CDC activity criteria, ps≥.673 (Table 2). Likewise, there were no differences for mFFABQ scores, 
ps≥.648 (Table 3) or for miniBESTest overall scores, ps≥.119 (Table 4) based on meeting CDC activity 
criteria. 
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Table 2. ABC scores with 95% CI for each life phase by level of activity. 
 
 CDC+ CDC- P value 
20s 67.5 
(56.1-79.0) 
84.7 
(51.1-118.5) 
0.7 
30s 68.2 
(56.9-79.5) 
84.6 
(42.7-126.5) 
0.7 
40s 67.8 
(55.3-80.4) 
75.0 
(50.1-100.0) 
0.8 
50s 67.8 
(55.3-80.4) 
75.0 
(50.1-100.0) 
0.8 
5 years 
preceding 
69.3 
(57.1-81.6) 
69.9 
(35.6-104.2) 
0.9 
Since 
diagnosis 
72.1 
(59.9-84.3) 
56.9 
(28.1-85.6) 
0.7 
 
 
 
 
Table 3. Modified FFABQ scores with 95% CI for each life phase by level of activity. 
 
 CDC+ CDC- P value 
20s 14.0 
(8.8-19.2) 
15.5 
(0.2-30.9) 
0.7 
30s 14.3 
(9.2-19.4) 
13.2 
(-5.8-32.1) 
0.7 
40s 14.6 
(8.9-20.2) 
12.8 
(1.6-24.0) 
0.6 
50s 14.6 
(8.9-20.2) 
12.8 
(1.6-24.0) 
0.6 
5 years 
preceding 
14.5 
(9.0-19.9) 
12.5 
(-2.8-27.8) 
0.7 
Since 
diagnosis 
13.8 
(8.2-19.4) 
15.9 
(2.8-29.0) 
0.6 
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Table 4. MiniBESTest scores with 95% CI for each life phase by level of activity. 
 
 CDC+ CDC- P value 
20s 21.8 
(19.6-24.0) 
21.4 
(15.0-27.8) 
0.16 
30s 21.9 
(19.7-24.0) 
20.3 
(12.5-28.2) 
0.15 
40s 21.8 
(19.5-24.2) 
21.5 
(16.9-26.2) 
0.16 
50s 21.8 
(19.5-24.2) 
21.5 
(16.9-26.2) 
0.16 
5 years 
preceding 
22.2 
(19.9-24.4) 
19.2 
(13.0-25.5) 
0.12 
Since 
diagnosis 
22.1 
(19.8-24.4) 
20.1 
(14.8-25.5) 
0.14 
 
 
There were no statistically significant differences between Val/Val and Met allele carriers on the ABC 
(p=.458), mFFABQ (p=.692), and minBESTest (p=.469) (Table 5). There were no statistically significant 
differences in fall history by CDC activity criteria at each life phase, ps≥.185 (Table 6). Likewise, there 
were no differences in Hoehn and Yahr proportions by CDC activity criteria for each life phase, ps≥.427 
(Table 7). 
 
Table 5. Descriptive statistics for the comparison of Val/Val and Met allele carriers for the ABC, mFFABQ, 
and the MiniBESTest. 
 
 
  
Genotype 
 
Mean 
 
Standard Deviation 
ABC Val/Val 68.5 22.6 
 Val/Met 70.5 32.3 
mFFABQ Val/Val 13.8 9.6 
 Val/Met 14.7 15.5 
MiniBESTest Val/Val 21.6 4.5 
 Val/Met 21.9 6.9 
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Table 6. Numbers of participants with a fall history for each life phase by level of CDC activity. 
 
 CDC+  CDC-  P value 
 Faller vs. 
Nonfaller 
Injured vs. 
Noninjured 
Faller 
Faller vs. 
Nonfaller 
Injured vs 
Noninjured 
Faller 
 
20s 13:12 10:15 2:1 0:3 ≥ 0.47 
30s 13:13 10:16 1:1 0:2 ≥ 0.74 
40s 11:11 9:13 3:3 1:5 ≥ 0.54 
50s 11:11 9:13 3:3 1:5 ≥ 0.54 
5 years 
  preceding  
12:12 9:15 2:2 1:3 =1.00 
Since 
diagnosis 
11:12 10:13 3:2 0:5 ≥ 0.19 
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Table 7. Numbers of participants by Hoehn and Yahr stage for each life phase by level of CDC activity. 
 
 
 
 
 
 
 
 
  HY4  
30s 
3 
HY1 1 
HY1.5 14 
HY2 6 
HY3 2 
0.9 
0 
0 
1 
1 
0 
  HY4  
40s 
HY1 
HY1.5 
HY2 
HY3 
  HY 
50s 
HY1 
HY1.5 
HY2 
HY3 
  HY 
5 years 
preceding 
HY1 
HY1.5 
HY2 
HY3 
  HY 
Since 
diagnosis 
HY1 
HY1.5 
HY2 
HY3 
HY4 
CDC+ CDC- P value 
20s  0.9 
3 0  
HY1 1 0  
HY1.5 15 2  
HY2 7 1  
HY3 2 0  
 
 
2 
 
1 
0.8 
1 0  
12 3  
6 1  
1 
                                                                                                                                                                       1  
 
2 
 
1 
0.8 
1 0  
12 3  
6 1  
1 
                                                                                                                                                                       1  
  0.4 
2 1  
1 0  
14 1  
6 1  
1 
                                                                                                                                                                       1  
  0.7 
3 0  
1 0  
11 4  
6 1  
2 0  
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There were no statistically significant interactions for the ABC, mFFABQ, or miniBESTest for the 2 
(Val/Val and Val/Met or Met/Met) X 2 (CDC+ and CDC-) ANCOVAs (covariates entered: age, years since 
diagnosis, and DBS status) during the 20s (ps≥.112, Figure 3 for miniBESTest), 30s (ps≥.109, Figure 4 for 
miniBESTest), 40s (ps≥.316), 50s (ps≥.316), 5 years before (ps≥.318), and since diagnosis (ps≥.243) (Table 
8). 
 
 
Figure 3. MiniBESTest scores based on genotype and meeting CDC activity levels during the life phase of 
20-30 years of age. 
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Figure 4. MiniBESTest scores based on genotype and meeting CDC activity levels during the life phase of 
30-39 years of age. 
 
 
 
 
Table 8. Interaction p values and effect sizes for the ABC, mFFABQ, or MiniBESTest for the 2 (Val/Val and 
Val/Met or Met/Met) X 2 (CDC+ and CDC- for each life phase) ANCOVA. 
 
 ABC  mFFABQ miniBESTest 
 Interaction 
p value 
Partial eta 
squared 
Interaction 
p value 
Partial eta 
squared 
Interaction 
p value 
Partial eta 
squared 
20s 0.848 0.110 0.721 0.148 0.112 0.363 
30s 0.891 0.095 0.582 0.186 0.109 0.365 
40s 0.937 0.076 0.813 0.121 0.316 0.265 
50s 0.937 0.076 0.813 0.121 0.316 0.265 
5 years 
preceding 
0.973 0.054 0.801 0.125 0.318 0.264 
Since 
diagnosis 
0.518 0.203 0.393 0.240 0.243 0.293 
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Year of diagnosis was not statistically different between the two genotypes, p=.275. Likewise, there 
were no statistically significant differences for age of onset based on CDC activity levels at 20s (p=.457), 
30s (p=.964), 40s (p=.866), 50s (p=.866), 5 years preceding (p=.139), and since diagnosis (p=.082) (Figure 
5). There were no statistically significant interactions for disease severity (MDS-UPDRS III), ps≥.272 
(Table 9). 
 
 
Figure 5. Age of onset based on meeting CDC activity levels at each life phase. 
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Table 9. Interaction p values and effect sizes for the MDS-UPDRS III for the 2 (Val/Val and Val/Met or 
Met/Met) X 2 (CDC+ and CDC- for each life phase) ANCOVA. 
 
ABC 
  Interaction p value  Partial eta squared  
20s 0.370 0.247 
30s 0.453 0.222 
40s 0.357 0.251 
50s 0.357 0.251 
5 years 
preceding 
0.272 0.281 
Since 
diagnosis 
0.325 0.262 
Ag
e 
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DISCUSSION 
 
There were no statistically significant differences in the subject proportions meeting CDC activity criteria 
by BDNF genotype across each life phase. There were no statistically significant differences in ABC, 
mFFABQ, or miniBESTest scores for each life phase based on meeting CDC activity criteria. Val/Val allele 
carriers did not score significantly differently on the ABC, mFFABQ, or miniBESTest than their Met allele- 
carrying counterparts. Likewise, they did not show significant differences in fall history, Hoehn and Yahr 
proportions, age of onset, or disease severity. From these results, it cannot be concluded that BDNF 
genotype interacts with lifetime self-reported physical activity levels to affect the degree of disease 
severity and age of onset in individuals with PD. 
 
 
Self-reported levels of physical activity were remarkably high for the sample tested at all age groups 
with 78% to 89% of the participants reporting having met CDC recommendations for physical activity at 
all stages of their lives (Table 1). In comparison, only 51% of adults in the United States report meeting 
CDC guidelines for aerobic exercise.48 Additionally, adults tend to over-estimate their time engaging in 
exercise. A study by Tucker et al found that while 62% of a representative sample of Americans self- 
reported meeting 2008 Physical Activity Guidelines for Americans, only 9.6% of participants actually met 
the guidelines as measured by accelerometer, a pattern that was consistent at all age groups (20s, 30s, 
40s, 50s, 60s, >70).49 Thus, it is possible that participants in this study also overestimated their physical 
activity levels. 
 
 
The nature and recruitment strategy used in this study may have encouraged even higher incidences of 
over-reporting physical activity. Participants were told they were participating in a study about the 
relationship between physical activity and disease progression. It is possible some unconsciously over- 
estimated their past exercise, believing it to be a possible modifiable risk factor for their current health 
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status. There may have also been response bias among participants to make themselves appear more 
active as participants were not told the researchers would be blinded to their responses. Alternatively, 
those agreeing to volunteer for the study may have been motivated to do so because they had a high 
level of past and/or current physical activity; thus, they may not be a true representative sample of the 
PD population. A larger sample size or alternative recruiting strategies to target individuals with PD who 
are less likely to participate in research studies may mitigate these possible effects. 
 
 
Despite the high number of participants reporting having met CDC recommended levels of physical 
activity throughout their lives, descriptive statistics and initial data analysis showed little difference 
between the Val/Val and Met carriers in the number of participants who reported meeting/not meeting 
CDC recommended levels of physical activity (p >0.8) (Table 1). Likewise, there was little difference in 
measures of gait and balance including the ABC, FFABQ, and miniBEST between participants reporting to 
have met or not met CDC guidelines of physical activity at each stage of life (Tables 2-4). The difference 
between the mean scores of the three outcome measures (ABC, FFABQ, and miniBEST) was also within 
the standard of error regardless of the participants’ genotypes (Table 5). Additionally, participants who 
had or had not met CDC recommended levels of physical activity demonstrated no difference in fall 
history (p > 0.185) (Table 6) or differences in Hoehn and Yahr scores (Table 7). This is consistent with our 
hypothesis that levels of physical activity or BDNF genotype individually are not sufficient to affect 
measures of gait and balance or disease severity in individuals with PD although the study is currently 
underpowered. 
 
 
Even though the aforementioned results were largely consistent between groups, one note-worthy 
difference was between the Met carriers and Val/Val participants 5 years prior to diagnosis when 
looking at the ABC. There was no statistically significant interaction between the ABC, mFFABQ, or the 
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miniBEST with regards to participants’ age, years since diagnosis, and DBS status (Table 8). However, the 
combination of BDNF genotype and CDC recommended level of aerobic exercise during the 5 years prior 
to diagnosis tended to affect ABC scores (ps =0.272) more than other outcome measures, although the 
interaction is not considered significant at this time (Table 9). If this trend continues with a larger 
sample, there may be a correlation between physical activity and the prodromal stage of PD depending 
on BDNF genotype. Future research may benefit from looking at the desire or ability to exercise during 
this prodromal stage in individuals who are Met allele carriers compared to their homozygous 
counterparts pending verification of these early patterns in data. 
An interesting trend also appeared at the ages of 20-29 years and 30-39 years with the miniBEST (Fig 3- 
4). Participants who were Val/Met and reported not meeting CDC activity criteria actually had higher 
average miniBEST scores than their same genotypic counterparts who reported meeting CDC activity 
criteria. In contrast, participants with the Val/Val genotype and reported not meeting the CDC levels for 
activity performed worse on the miniBEST than their same genotypic counterparts who reported 
meeting CDC recommended physical activity levels. If this trend continues with a larger sample size, this 
may indicate that individuals with the homozygous Val/Val BDNF genotype may benefit more from 
aerobic exercise during their 20s to 40s than individuals with the heterozygous Val/Met genotype to 
improve balance and gait after they are diagnosed with PD. If correct, this could strengthen the 
argument for BDNF genetic testing and prescribing aerobic exercise for individuals who are Val/Val and 
at increased risk for being diagnosed with PD in the future. 
 
 
Age of onset also presented some remarkable trends despite being underpowered. Participants who 
reported having met CDC recommended levels of activity at each phase of life tended to have a later 
diagnosis of PD than participants who reported not having met CDC recommended activity levels (Fig. 5). 
This is consistent with previous studies that demonstrate physical activity may be a modifiable risk 
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factor for the diagnosis of PD.5–9 If this trend continues as research progresses, it may demonstrate that 
exercise not only lowers the chance of being diagnosed with PD, but also delays its onset, which would 
be a novel finding. 
 
 
Despite some interesting initial trends in the data, at this early stage in research, we cannot confirm 
whether or not measures of gait and balance or age of onset of PD are correlated with BDNF genotype 
and physical activity. This correlation would require a larger sample size due to the high number of 
factors that have been shown to be correlated with PD,5,50,51 and therefore, may have different disease 
etiologies and progressions which were not captured in this study. 
 
 
The primary limitation to our study is a small sample size. MiniBESTest scores in relation to lifetime self- 
reported history of physical activity had the strongest trend toward significance with p < 0.162 (Table 4). 
Using the effect sizes from Table 8 ranging from 0.262-0.365, the necessary sample size to achieve 
significance was estimated to be from 32 to 197 participants, which is greater than the number in the 
current study. Other limitations to our study include the reliability of the novel LPAQ that was used to 
quantify physical activity over lifespan as previously discussed. The nature of self-reported data is 
inherently less reliable than objective measures, and faults in recall may increase with participant age or 
cognitive decline short of dementia. All tests were performed in accordance with published protocols. As 
previously mentioned, most participants were recruited from other research studies, most of which 
investigated the effects of exercise, or were informed of the focus of the study prior to participating, 
leading to possible sample recruitment biases. 
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CONCLUSION 
 
In conclusion, our results do not indicate a significant relationship between BDNF genotype and lifetime 
history of physical activity at this time. Likewise, these early results do not support a link between age of 
onset, disease severity, or postural instability in PD. Participants in our sample with the Val/Val 
polymorphism and high levels of lifetime physical activity do not present with significantly later onset, 
lesser severity, or higher postural instability than their heterozygous Val/Met counterparts. These 
results should be considered preliminary at this time due to being underpowered and will be 
reevaluated when an adequate sample has been tested. Data collection is currently on-going. The 
validity and reliability of the LPAQ will also continue to be investigated with a larger sample size to 
determine the role of lifetime physical activity and its relationship to BDNF genotype and disease 
progression. Significance on this measure may shed light on the need for more objective physical activity 
measurements at certain time points in individual’s lives either before or after being diagnosed with PD 
to better understand the influence of genetics on disease trajectory. 
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